The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...

Onapgo is approved for adult Parkinson’s patients experiencing motor fluctuations. Credit: Inside Creative House via Getty Images. · Pharmaceutical Technology · Inside Creative House via Getty Images.

Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically planning ...

Levodopa is the gold standard for Parkinson's disease treatment, but not all patients find success with commonly prescribed tablets and pills. For those with limited motor control, a more sustainable ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

Indian clinical trial data for drugs like safinamide and apomorphine pump therapy are key for global pharma to seek US FDA approval. This along with specific therapies like gene based treatments ...

After successfully launching the D-mine Pump, a micro infusion device designed to provide precise continuous subcutaneous drug delivery for PD patients, the product family has been extended to include ...

The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump. After two prior attempts to win FDA approval for its apomorphine infusion device for the continuous ...

SALZBURG, Austria--(BUSINESS WIRE)--Launched as the D-mine ® Pump, this portable micro infusion device recently received European CE approval and is currently being launched in several European ...